CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study

Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee

Clin Mol Hepatol. 2018;24(3):311-318. Published online 2018 June 4 DOI: https://doi.org/10.3350/cmh.2017.0070

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study

Clinical and Molecular Hepatology. 2018;24(3):311-318

Link1

Link2 Link3

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Graham R. Foster, Stephen Pianko, Ashley Brown, Daniel Forton, Ronald G. Nahass, Jacob George, Eleanor Barnes, Diana M. Brainard, Benedetta Massetto, Ming Lin, Bin Han, John G. McHutchison, G. Mani Subramanian, Curtis Cooper, Kosh Agarwal

Gastroenterology. 2015;149(6):1462-1470

Link1 Link2

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis

Tingting Tao, Xuehua Jiang, Yuehong Chen, Yiran Song

International Journal of Infectious Diseases. 2017;55:56-71

Link1 Link2

A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in egyptian adolescents with chronic hepatitis C virus Infection

M. El-Sayed, M. Hassany, N. Asem

Journal of Hepatology. 2017;66(1):S178

Link1 Link2

Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success?

Federico Sáez‐Royuela, Ester Badia

Liver International. 2016;36(8):1093-1095

Link1 Link2 Link3

Efficacy and safety of sofosbuvir-containing regimen for Korean patients with chronic hepatitis C virus infection: A retrospective, nationwide, real-world study

S.-H. Jeong, E.S. Jang, K.-A. Kim, I.H. Kim, W.J. Chung

Journal of Hepatology. 2018;68:S298-S299

Link1 Link2

P1‐092: The efficacy of sofosbuvir/velpatasvir/ribavirin in cirrhotic, genotype 3a HCV patients, previously failures to sofosbuvir/daclatasvir/ribavirin combination

Journal of Viral Hepatitis. 2018;25(S2):71-71

Link1 Link2

RETRACTED ARTICLE: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice

Sherief Abd-Elsalam, Mohamed Sharaf-Eldin, Shaimaa Soliman, Asem Elfert, Rehab Badawi, Youssef K. Ahmad

Archives of Virology. 2017;163(1):51-56

Link1 Link2

Link3

Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2

Naoshi Nishida, Masashi Kono, Tomohiro Minami, Hirokazu Chishina, Tadaaki Arizumi, Masahiro Takita, Norihisa Yada, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Tashiharu Sakurai, Masatoshi Kudo

Digestive Diseases. 2016;34(6):632-639

Link1 Link2 Link3

Retraction Note to: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice

Sherief Abd-Elsalam, Mohamed Sharaf-Eldin, Shaimaa Soliman, Asem Elfert, Rehab Badawi, Youssef K. Ahmad

Archives of Virology. 2022;167(11):2441-2441

Link1

Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.